Medical Plasmas
Medical Plasmas is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Medical Plasmas.
Medical Plasmas is a company.
Key people at Medical Plasmas.
Medical Plasmas is a technology company developing cold atmospheric pressure plasma systems for treating chronic and acute wounds. It builds the world's first air cold plasma jet medical device, which stimulates tissue regeneration, deactivates microorganisms without damaging living tissue, accelerates healing, reduces bacterial load, and improves microcirculation—addressing challenges like non-healing wounds and antibiotic resistance in a safe, effective, drug-free manner.[3][5] The company serves patients with chronic injuries, hospitals, and clinics, particularly through collaborations like compassionate use treatments at the Clinic University of Navarra, where a clinical trial is underway for CE marking of its PlasmAction Med device; it solves persistent wound healing issues by promoting oxygen saturation, nutrient supply, and pathogen inactivation without necrosis or resistance development.[3][5]
Medical Plasmas emerged from advancements in plasma medicine, a field coined two decades ago with rapid growth in research across Europe, the US, and Asia. Key milestones include FDA approval for dermatological applications in 2008, Germany's first clinical trial for wound treatment in 2010, and approval in 2013—demonstrating the technology's evolution from lab experiments to clinical use.[5] The company maintains active ties with institutions like the Clinic University of Navarra for trials and implementation, positioning it as a pioneer in bringing cold plasma jets to reference hospitals.[5]
Medical Plasmas rides the plasma medicine trend, an emerging field exploding with research on non-thermal plasma's interactions with cells and tissues for wound treatment, pathogen inactivation (including biofilms), and tissue regeneration. Timing aligns with global crises in antibiotic-resistant bacteria and chronic wounds, amplified by post-2008 FDA nods and European approvals, amid multiplying efforts in hospitals worldwide.[5][7] Market forces favor it through "Made in [relevant region]" quality seals (similar to peers), international demand for drug-free solutions, and collaborations accelerating clinical adoption—positioning plasma tech as a disruptor in regenerative medicine and infection control.[1][5]
Medical Plasmas is poised for regulatory wins like CE marking via trials at Clinic University of Navarra, enabling broader hospital rollout and potential FDA pursuits amid plasma medicine's tremendous growth. Trends like rising antimicrobial resistance and demand for non-invasive healing will propel it, evolving its influence from pioneer to standard in wound care—ultimately restoring quality of life for chronic injury patients as cold plasma enters mainstream medicine.[3][5]
Key people at Medical Plasmas.
